期刊文献+

沐舒坦辅助治疗婴幼儿支气管肺炎临床观察 被引量:2

Ambroxol adjuvant treatment of bronchial pneumonia in infants and young children the clinical observation
暂未订购
导出
摘要 目的:探讨沐舒坦注射液辅助治疗婴幼儿支气管肺炎的疗效。方法:治疗组45例在常规治疗的基础上,加用沐舒坦注射液7.5mg/次,2次/天,疗程5-7天雾化吸入。对照组45例综合常规治疗的基础上,加用生理盐水+α糜蛋白酶5mg超声雾化吸入,2次/天,疗程5-7天。比较两组患儿的症状与体征。结果:治疗组应用沐舒坦注射液辅助治疗婴幼儿支气管肺炎在咳嗽、痰鸣消失天数及罗音消失时间、住院天数均较对照组明显缩短。结论:沐舒坦注射液辅助治疗婴幼儿支气管肺炎,可缩短住院天数,迅速改善症状,明显提高疗效,尤其祛痰和减少肺部湿性罗音的效果较好。 Objective:Mucosolvan Injection in Treatment of infants with bronchopneumonia effect. Methods :45 patients treated on the basis of routine treatment, plus ambroxol injection 7.5mg/time ,2times/day,5 -7 days of inhalation treatment. Control group 45 cases on the basis of comprehensive routine treatment, plus 5mg with saline + a chymotrypsin ultrasonic atomizing inhalation ,2times/day, Course of 5 -7 days. Compared two groups of children with symptoms and signs. Results:The application of Ambroxol Injection in Treatment of bronchial pneumonia in infants and young children cough, sputum, and rales disappeared days lost time,length of hospital stay was significantly shorter than in the control group. Condusions:Ambroxol Injection in Treatment of bronchial pneumonia in infants and young children can shorten the hospital stay and rapid improvements in symptoms,increase the treatment effficiency,in particular,expectorant,and to reduce the effect of moist tale good.
作者 孟庆梅
出处 《医学信息(中旬刊)》 2010年第12期3742-3743,共2页 Medical Information Operations Sciences Fascicule
关键词 沐舒坦 辅助治疗 支气管肺炎 吸入法 Ambroxol Adjuvant therapy Bronchial pneumonia Inhalation
  • 相关文献

参考文献3

  • 1诸福棠,江载芳.诸福棠实用儿科学[M].6版.北京:人民卫生出版社,1997:1141.
  • 2朱科明,李深,邓小明.沐舒坦对危重患者肺功能的保护[J].中国急救医学,2001,21(1):59-60. 被引量:155
  • 3Gillissen A, Nowak D. Characterization of N - acetylcysteine and ambroxol in anti - oxidant therapy [ J ]. Respir Med, 1998,92 ( 4 ) : 609 - 623.

二级参考文献15

  • 1Lusuardi M,Cape 1 li A,Carli S,etal.Role of surfactant in chronic obst ructive pulmonary disease:therapeuticimplications.Respiration,1992,59(Suppl 1): 28-32.
  • 2Gillissen A,Nowak D.Characterization of N-acetylcysteine and ambroxol inanti-oxedant therapy.Respir Med,1998,92(4):609-623.
  • 3Houtmeyers E.Effects of drugs on mucus clearance.Eur Respir J,1999,1 4(2):452-467.
  • 4Zasshi NY.Effects of ambroxol HC1 on the guinea pig tracheal mucous secretion andthe rat pulmonary surfactant secretion.Uchida-M,1992,100(4):293-30 0.
  • 5Derelle J,Bertolo HE,Marchal F,et al.Respiratory evolution of patien t withmucoviscidosis treated with mucolytic agents plus dornase alfa.Arch-Pediatr,1998,5(4):371-377.
  • 6Nowak D,Antczak A,Krol M,et al.Antioxidant properties of ambroxol.Fr ee Radic BiolMed,1994,16(4):517-522.
  • 7Zwablo KG,Servais MD,Schmutzler W,et al.Ambroxol inhibits histamine release fromhuman adenoidal mast cells.Inflamm Res,1998,47(Suppl 1):S16-17.
  • 8Dorow P,Weiss T.Modification of mucociliary clearance by a combinati on oftheophylline with ambroxol and of ambroxol in monotherapy.Arzneimittelforschung,1988,38(6):828-830.
  • 9Tamaoki J.Ambroxol inhibits Na+ absorption by canine airway epithe lial cells inculture.J-Pharm-Pharmacol,1991,43(12):841-843.
  • 10Michnar M,Milanowski J.Clinical evaluation of efficacy and tolerance oforaltreatment with ambroxol in patients with chronic bronchitis.Pneumonol-Alergol-Pol,1996,64(Suppl 1):90-96.

共引文献154

同被引文献9

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部